Authors: | Terrier, J.; Zanella, M. C.; Masouridi-Levrat, S.; Kronig, I.; Chalandon, Y.; Vernaz, N.; van Delden, C.; Papanicolaou, G.; Neofytos, D. |
Article Title: | Clinical and pharmacological considerations for concomitant administration of posaconazole and isavuconazole with letermovir |
Abstract: | We sought in this case-control retrospective study to compare posaconazole and isavuconazole (PCZ and IVC, respectively) plasma trough concentration (Ctrough) levels in high-risk allogeneic hematopoietic cell transplant (HCT) recipients who received letermovir (LET) or not. PCZ/IVC Ctrough levels were not found to be significantly different between cases and controls, as they were 1.31 mg/liter (median) (interquartile range [IQR], 0.90) versus 1.36 mg/liter (IQR, 1.16) (P = 0.31) and 3.20 mg/ liter (IQR, 2.40) versus 2.35 mg/liter (IQR, 1.50) (P = 0.17), respectively. In conclusion, we observed PCZ/IVC Ctrough levels within the expected range and no significant effect of LET coadministration. Copyright © 2021 American Society for Microbiology. All Rights Reserved. |
Keywords: | retrospective studies; pyridines; antifungal agent; hematopoietic stem cell transplantation; retrospective study; quinazolines; acetic acid; quinazoline derivative; posaconazole; antifungal agents; triazoles; nitriles; nitrile; triazole derivative; pyridine derivative; acetates; therapeutic drug monitoring; letermovir; isavuconazole; allogeneic hematopoietic cell transplant recipients |
Journal Title: | Antimicrobial Agents and Chemotherapy |
Volume: | 65 |
Issue: | 6 |
ISSN: | 0066-4804 |
Publisher: | American Society for Microbiology |
Date Published: | 2021-06-01 |
Start Page: | e00274-21 |
Language: | English |
DOI: | 10.1128/aac.00274-21 |
PUBMED: | 33782007 |
PROVIDER: | scopus |
PMCID: | PMC8316116 |
DOI/URL: | |
Notes: | Article -- Export Date: 1 July 2021 -- Source: Scopus |